XOMA CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.59 USD | +1.40% |
|
-6.15% | +32.92% |
| Apr. 03 | XOMA Corporation completed the acquisition of Kinnate Biopharma Inc.. | CI |
| Mar. 08 | XOMA Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
| Sales 2024 * | 14.1M | Sales 2025 * | 20.65M | Capitalization | 286M |
|---|---|---|---|---|---|
| Net income 2024 * | -24M | Net income 2025 * | -20M | EV / Sales 2024 * | 20.3 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 13.9 x |
| P/E ratio 2024 * |
-11.5
x | P/E ratio 2025 * |
-14.4
x | Employees | 13 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.58% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | +1.40% | ||
| 1 week | -6.15% | ||
| Current month | +2.25% | ||
| 1 month | -2.34% | ||
| 3 months | +28.74% | ||
| 6 months | +44.99% | ||
| Current year | +32.92% |
1 week
24.00
25.52
1 month
23.0027.00
Current year
18.5727.00
1 year
13.4827.00
3 years
13.4839.49
5 years
11.5846.32
10 years
3.96119.00
| Managers | Title | Age | Since |
|---|---|---|---|
Owen Hughes
CEO | Chief Executive Officer | 49 | 22-12-31 |
Thomas Burns
DFI | Director of Finance/CFO | 50 | 06-08-13 |
Bradley Sitko
CIO | Chief Investment Officer | 43 | 23-01-02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Heather Franklin
BRD | Director/Board Member | 58 | 21-08-05 |
| Chairman | 68 | 10-08-25 | |
Joseph Limber
BRD | Director/Board Member | 71 | 12-12-11 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.22% | 27 M€ | -7.00% | - | |
| 0.00% | 34 M€ | +1.04% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 24.59 | +1.40% | 14,874 |
| 24-04-17 | 24.25 | -0.53% | 9,027 |
| 24-04-16 | 24.38 | +0.16% | 7,189 |
| 24-04-15 | 24.34 | -5.84% | 6,099 |
| 24-04-12 | 25.85 | -1.34% | 11,226 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotes
XOMA Corporation is a biotechnology royalty aggregator. The Companyâs royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Its royalty portfolio includes DAY101 (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, TAK-079 (mezagitamab), BAY-1213790 (osocimab), AFM13 (acimtamig), AB023 (gruticibart), AB002 (E-WE thrombin), AB054, AV-299 (ficlatuzumab), COM902, vosaroxin, aldoxorubicin, INCAGN2385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, G03-52-01, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], VABYSMO (faricimab-svoa), CMP-001 (vidutolimod), and CFZ533 (iscalimab).
Calendar
2024-05-06
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
24.59
USD
Average target price
74
USD
Spread / Average Target
+200.94%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +32.92% | 286M | |
| -3.30% | 102B | |
| +1.79% | 96.07B | |
| -1.43% | 21.66B | |
| -18.35% | 20.77B | |
| -8.65% | 18.53B | |
| -40.31% | 16.91B | |
| -26.84% | 13.79B | |
| +0.59% | 13.33B | |
| +20.86% | 10.94B |
- Stock Market
- Equities
- XOMA Stock
